Ghosh S K, De Vos C, McIlroy I, Patel K R
Department of Respiratory Medicine, Western Infirmary, Glasgow.
Thorax. 1991 Apr;46(4):242-4. doi: 10.1136/thx.46.4.242.
The effect of oral and inhaled cetirizine, a potent and specific H1 receptor antagonist, was studied in patients with exercise induced asthma. Twelve patients (five male; mean age 35.2 years) were given oral placebo or cetirizine 10 mg twice daily for one week, double blind and in randomised order, and exercised on a treadmill for six to eight minutes at a submaximal work load two hours after the final dose. There was no significant change in baseline FEV1 after treatment and cetirizine failed to inhibit exercise induced bronchoconstriction (maximum falls in FEV1 28% and 27% of baseline). In a further eight patients (four male; mean age 40.8 years) the effect of 1 ml cetirizine (5 and 10 mg/ml) given through a Wright nebuliser was compared with that of placebo in a double blind trial. The fall in FEV1 after exercise was reduced after both concentrations of cetirizine by 15.2% of baseline after 5 mg/ml and by 10.2% after 10 mg/ml, compared with 23.7% after placebo. In two patients cetirizine had no effect. In a further study cetirizine (10 mg/ml) given by inhalation displaced the geometric mean PC20 histamine 13.1 fold to the right by comparison with placebo. The reason for the difference between the effects of oral and of inhaled cetirizine on exercise asthma is not clear but may be related to differences in local concentration in the airway.
在运动诱发性哮喘患者中研究了强效特异性H1受体拮抗剂西替利嗪口服和吸入给药的效果。12例患者(5例男性,平均年龄35.2岁)接受口服安慰剂或西替利嗪10毫克,每日两次,共一周,采用双盲随机顺序给药,在最后一剂后两小时于跑步机上以亚最大负荷运动6至8分钟。治疗后基线第一秒用力呼气量(FEV1)无显著变化,西替利嗪未能抑制运动诱发的支气管收缩(FEV1最大下降幅度为基线的28%和27%)。在另外8例患者(4例男性,平均年龄40.8岁)中,通过双盲试验比较了用Wright雾化器给予1毫升西替利嗪(5毫克/毫升和10毫克/毫升)与安慰剂的效果。与安慰剂组FEV1运动后下降23.7%相比,两种浓度的西替利嗪治疗后FEV1运动后下降幅度均减小,5毫克/毫升时为基线的15.2%,10毫克/毫升时为10.2%。有2例患者中西替利嗪无效。在另一项研究中,与安慰剂相比,吸入西替利嗪(10毫克/毫升)使组胺激发试验的半数激发浓度(PC20)几何均值右移13.1倍。口服和吸入西替利嗪对运动性哮喘疗效不同的原因尚不清楚,但可能与气道局部浓度差异有关。